Stomachs can be transplanted, but the procedure is almost never performed in isolation. Instead, the stomach is typically included as part of a multivisceral transplant, where multiple abdominal organs are replaced together as a single block. This makes stomach transplantation one of the rarest and most complex operations in modern surgery, performed at only a handful of specialized centers worldwide. The reasons it exists, who qualifies, and what happens afterward tell a fascinating story about the limits of what transplant medicine can achieve.
Why the Stomach Is Almost Never Transplanted Alone
When most people hear “organ transplant,” they think of a single organ swapped out for a donor organ: a new heart, a new kidney, a new liver. The stomach doesn’t work that way. The diseases severe enough to destroy the stomach rarely leave the surrounding organs untouched. The stomach sits at a crossroads of blood supply, nerve connections, and digestive plumbing shared with the pancreas, duodenum, and small intestine. By the time a patient’s stomach has failed badly enough to warrant replacement, the damage usually extends to neighboring structures too.
There are fundamentally four types of gut transplantation: isolated small bowel transplant, combined liver and small bowel transplant, full multivisceral transplant, and modified multivisceral transplant.1PubMed Central. Current status of intestinal and multivisceral transplantation In a full multivisceral transplant, the stomach, duodenum, pancreas, and intestine are transplanted together as one connected unit, often with the liver included. In the modified version, the liver is spared. At one major transplant center, out of 121 multivisceral transplants performed, about 70% included the liver and 30% excluded it.2Journal of Gastrointestinal Surgery. Modified “Liver-Sparing” Multivisceral Transplant with Preserved Native Spleen, Pancreas, and Duodenum: Technique and Long-Term Outcome In both versions, the stomach comes along as part of the package rather than being transplanted on its own.
Who Needs a Stomach Transplant
The patients who end up receiving a new stomach are a small and critically ill group. The most common reason adults need any kind of intestinal or multivisceral transplant is short gut syndrome, which accounted for about 65% of cases in recent registry data.3Intestinal Failure. National trends in intestinal and multivisceral transplantation in the United States: A 30-year UNOS registry analysis Short gut syndrome occurs when so much of the intestine has been surgically removed or damaged that the body can no longer absorb enough nutrition from food. Patients survive on intravenous feeding, called total parenteral nutrition, which sustains them but carries serious long-term risks including liver failure, bloodstream infections, and loss of intravenous access sites.
Some patients need stomach inclusion specifically because of conditions that destroy the upper digestive tract. Familial adenomatous polyposis, a genetic condition that causes precancerous growths throughout the gut, is one example. Patients with this disease sometimes develop aggressive tumors called desmoids that invade the abdominal organs, or they develop large growths in the stomach and duodenum that risk turning cancerous. When these patients have already lost most of their intestine from prior surgeries, a multivisceral transplant including the stomach becomes the only viable option.4PubMed Central. Intestinal transplantation in Familial Adenomatous Polyposis In children, the picture is different: functional bowel problems and birth defects like gastroschisis, where the intestines develop outside the body, are leading reasons for transplant.3Intestinal Failure. National trends in intestinal and multivisceral transplantation in the United States: A 30-year UNOS registry analysis
In all these cases, transplantation is a last resort. Patients are referred only after other treatments have failed and the complications of long-term intravenous feeding are becoming life-threatening. The evaluation process is extensive, often taking months, and involves teams of surgeons, gastroenterologists, nutritionists, and psychologists.
What the Surgery Actually Involves
A multivisceral transplant that includes the stomach is among the longest and most technically demanding operations in surgery. The procedure can last anywhere from eight to eighteen hours, sometimes longer. The surgeon removes the patient’s diseased abdominal organs, then implants the donor organ block, connecting blood vessels, bile ducts, and the digestive tract in sequence. The stomach is transplanted still attached to the donor’s duodenum and pancreas, preserving the anatomical relationships that allow these organs to function together.
Blood supply is a critical concern. The stomach depends on a web of arteries, and preserving or reconstructing these connections determines whether the transplanted organ survives. Research on related abdominal surgeries has found that preserving or reconstructing the key arteries and veins that feed the stomach dramatically improves the odds of keeping the organ viable.5PubMed. Stomach preservation in pancreatectomy with celiac axis resection: Prediction and technique via Mayo Clinic classification The same principle applies in transplantation: the surgical team meticulously reconnects blood vessels to ensure the new stomach receives adequate blood flow from the moment it is implanted.
Because the vagus nerve, which controls stomach contractions and acid secretion, is severed during the transplant, the new stomach does not function the way the original one did. It cannot receive the brain’s normal signals to churn food and regulate emptying. This is one reason the recovery process is so prolonged and why many patients experience motility problems afterward.
Why the Gut Is So Hard to Transplant
The intestinal tract, including the stomach, is arguably the most immunologically challenging organ system to transplant. The gut contains an enormous amount of lymphoid tissue, the immune cells that normally protect against infections from food and bacteria. When a donor gut is placed into a recipient, those donor immune cells come along for the ride. This creates a two-way immunological battle: the recipient’s immune system attacks the foreign organ (rejection), and the donor’s immune cells can attack the recipient’s body (graft-versus-host disease).6PubMed Central. Intestinal Transplant Immunology and Intestinal Graft Rejection: From Basic Mechanisms to Potential Biomarkers
Rejection of the transplanted stomach is monitored through regular biopsies, where small tissue samples are examined under a microscope. A specific grading system exists for gastric allografts that evaluates changes in the surface lining, underlying tissue, and glandular structures, assigning a score that determines the severity of rejection.7PubMed. Acute cellular rejection grading scheme for human gastric allografts This grading system gives transplant teams a standardized way to catch rejection early and adjust treatment.
Graft-versus-host disease is the flip side of the coin. Research has identified a specific type of donor immune cell, called resident memory T cells, that appears to drive this complication. In a study comparing intestinal transplant patients who developed graft-versus-host disease with those who did not, the affected patients had significantly higher levels of these donor-derived immune cells circulating in their blood and residing in the transplanted organ.8PubMed Central. CD69+ resident memory T cells are associated with graft-versus-host disease in intestinal transplantation Understanding this mechanism is helping researchers develop better ways to predict and potentially prevent the complication.
To keep these immune attacks in check, patients take powerful immunosuppressive drugs for the rest of their lives. These medications carry their own serious side effects, including increased vulnerability to infections, kidney damage, and a heightened risk of certain cancers.
Survival Rates and How They Have Improved
Survival after intestinal and multivisceral transplantation has improved substantially over the past three decades, though it still lags behind outcomes for more common organ transplants like kidneys or livers. According to the 2025 International Intestinal Transplant Registry report, overall five-year patient survival stands at about 60% for children and 52% for adults, with graft survival slightly lower at 51% and 46% respectively.9PubMed Central. Intestinal and Multivisceral Transplantation: Where We Stand Today
A 30-year analysis of U.S. registry data illustrates how dramatically outcomes have changed. In the earliest era of these transplants, five-year survival for children was around 46%. By the most recent era, that number had climbed to roughly 72%.3Intestinal Failure. National trends in intestinal and multivisceral transplantation in the United States: A 30-year UNOS registry analysis Adult survival improved in the middle era but has plateaued more recently, hovering around 52% at five years. The gains in pediatric outcomes reflect improvements in surgical technique, better immunosuppression protocols, and more experienced post-operative care at high-volume centers.
Some individual centers report outcomes that exceed the registry averages. One experienced program published three-, five-, and ten-year overall patient survival rates of roughly 70%, 66%, and 63% respectively.10PubMed Central. Long-term survival in visceral transplant recipients in the new era: A single-center experience That ten-year figure is encouraging because it suggests that patients who make it past the dangerous first few years have a reasonable chance of long-term survival. The gap between top centers and the broader registry highlights how much center experience matters in this field. There are only a small number of programs worldwide performing these operations regularly, and volume correlates with outcomes.
Complications Beyond Rejection
Even when the transplant itself is successful and rejection is controlled, patients face a gauntlet of potential complications. One of the most concerning is post-transplant lymphoproliferative disorder, a type of cancer linked to immunosuppression. In a pediatric series, the incidence was about 14%, with most cases appearing within the first year after transplant. The condition was strongly associated with active Epstein-Barr virus infection, and nearly half the affected patients required removal of the transplanted organ. Patient survival among those who developed it was about two-thirds.11PubMed. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome
Gastric motility disorders are another common problem. Because the vagus nerve is cut during transplantation, the new stomach often has trouble emptying properly. This problem is not unique to stomach transplants; it affects patients after many types of organ transplants. The prevalence of gastroparesis after lung transplants, for instance, runs as high as 40 to 91% due to vagal nerve injury, and the condition carries a 2.7-fold increased risk of death or retransplantation in that population.12PubMed Central. Gastric Motility Disorders Post Organ Transplantation-A Comprehensive Review For patients who receive a transplanted stomach, motility issues can mean persistent nausea, vomiting, and difficulty eating, problems that directly undermine the whole purpose of the transplant.
Infections are a constant threat. The combination of heavy immunosuppression and a gut full of bacteria creates fertile ground for serious infections, from bacterial bloodstream infections to invasive fungal diseases. Careful monitoring, prophylactic antibiotics, and close follow-up are standard, but infections remain one of the leading causes of death after these transplants.
Life After a Multivisceral Transplant
Recovery from a multivisceral transplant is measured in months and years, not weeks. Most patients spend several weeks in the hospital after surgery, with many requiring time in the intensive care unit. The transition from intravenous nutrition to eating by mouth is gradual and often difficult. The transplanted stomach and intestine need time to begin working together, and many patients struggle with appetite, food tolerance, and the psychological adjustment of eating again after months or years on intravenous feeding.
Children face particular challenges. Learning to eat, or relearning after a long period of intravenous nutrition, involves not just physical recovery but behavioral and sensory adjustment. Many pediatric transplant recipients have never eaten normally and need specialized support from feeding therapists.13PubMed. Factors Impacting on Eating in Pediatric Intestinal-Transplant Recipients: A Mixed-Methods Study The process can take months, and some children remain partially dependent on supplemental feeding for a long time.
For patients who do recover well, the transplant can be transformative. Freedom from intravenous nutrition means no more central line infections, no more hours hooked up to an infusion pump, and the ability to travel and participate in daily life more normally. But the trade-off is lifelong medication, frequent clinic visits, regular biopsies to monitor for rejection, and the ongoing risk of complications. It is not a cure so much as an exchange of one set of medical burdens for another, ideally less dangerous set.
Alternatives to Transplanting the Stomach
For patients whose primary problem is a stomach that won’t empty rather than one that needs to be entirely replaced, several less invasive options exist. Gastric electrical stimulation uses an implanted device that delivers mild electrical pulses to the stomach wall, improving symptoms and helping patients return to normal oral nutrition. Studies have found it effective enough to serve as a genuine alternative to removing the stomach entirely in patients with severe, treatment-resistant gastroparesis.14JAMA Surgery. Gastric Electrical Stimulation: An Alternative Surgical Therapy for Patients With Gastroparesis Newer procedures like pyloromyotomy and pyloroplasty, which reduce resistance at the stomach’s outlet valve, are also being used alongside or instead of electrical stimulation.15PubMed Central. Gastric Electric Stimulation for Refractory Gastroparesis
For post-transplant gastroparesis specifically, the treatment toolkit has expanded. Prokinetic drugs, which stimulate stomach contractions, produce improvement in roughly 60 to 80% of patients. An endoscopic procedure called G-POEM, where the pyloric muscle is cut from the inside using a scope rather than open surgery, has shown success rates around 85%. Gastric electrical stimulation has also been applied in the transplant population with reported quality-of-life improvements.12PubMed Central. Gastric Motility Disorders Post Organ Transplantation-A Comprehensive Review These options mean that many motility problems can be managed without a second transplant.
Bioengineered Stomachs and the Future
The idea of growing a replacement stomach in a lab sounds like science fiction, but early-stage research is underway. One approach involves taking a pig stomach, stripping away all its cells through a process called decellularization, and using the remaining scaffold of structural proteins as a framework to grow human cells on. Researchers have successfully produced these cell-free scaffolds from porcine stomachs while preserving the collagen and elastin that give stomach tissue its strength and flexibility. When human liver cells were seeded onto these scaffolds in laboratory experiments, the cells survived and multiplied, demonstrating that the material is compatible with human cell growth.16PubMed Central. Stomach engineering: region-specific characterization of the decellularized porcine stomach
The work is still at a very early stage. The mechanical properties of decellularized stomach tissue change during the process, with some measures of strength dropping, and nobody has yet produced a functional bioengineered stomach that can contract, secrete acid, and process food the way a real one does. The stomach is a more complex organ than, say, a bladder or a blood vessel, structures where tissue engineering has made more progress. Still, the fact that the scaffolding approach is being actively explored for the stomach specifically is a sign that the transplant community recognizes the need for alternatives to donor organs. Demand already far outstrips supply for intestinal transplants, and a lab-grown option, even decades away, could eventually change the calculus for patients who currently have no good options.
How Centers Decide Whether to Include the Stomach
Not every multivisceral transplant includes the stomach. The decision depends on the extent of the patient’s disease, the condition of their native stomach, and the surgical team’s assessment of what can be preserved. Some patients have a perfectly functional stomach but devastated intestines, in which case the transplant can be designed to keep the native stomach in place while replacing everything downstream. Others have disease that involves the stomach directly, whether from tumor invasion, compromised blood supply, or structural damage from prior surgeries, making inclusion of the stomach unavoidable.
Combined liver and intestine recipients may actually have better post-transplant survival than those who receive intestine alone, thanks to the liver’s immunological benefits. The liver appears to exert a protective effect on the transplanted bowel, dampening the immune response against it.1PubMed Central. Current status of intestinal and multivisceral transplantation This has influenced surgical planning: when a patient needs a liver transplant anyway, there is an argument for including the intestine and stomach in the same operation rather than performing separate procedures, since the liver may help protect the other grafted organs from rejection.
These decisions are made on a case-by-case basis by multidisciplinary teams at transplant centers. There is no universal algorithm. The surgeon’s experience, the center’s outcomes data, the donor organ availability, and the patient’s overall fitness all factor in. This individualized approach is part of why the field remains concentrated at a few high-volume centers where teams have seen enough cases to make these judgment calls with confidence.
The Immunosuppression Balancing Act
The medications that keep a transplanted stomach and intestine alive create their own cascade of problems. Tacrolimus, the backbone of most post-transplant regimens, can paradoxically affect gut motility in both directions: it tends to speed up intestinal movement while other common drugs like mycophenolate impair it.12PubMed Central. Gastric Motility Disorders Post Organ Transplantation-A Comprehensive Review These competing effects mean that the same drugs keeping the organ alive can make it function poorly, requiring careful dose adjustment and sometimes additional medications to counteract side effects.
Post-transplant diabetes is another consequence. Immunosuppressive drugs damage insulin-producing cells over time, and the resulting diabetes further worsens gastric motility. In kidney transplant recipients, post-transplant diabetes carries more than a fivefold increased odds of developing gastroparesis.12PubMed Central. Gastric Motility Disorders Post Organ Transplantation-A Comprehensive Review Similar dynamics likely apply to multivisceral recipients, compounding an already complex situation. The gut microbiome also shifts after transplantation, with changes in the balance of bacterial populations that may contribute to motility problems and immune complications. Researchers have documented reductions in certain beneficial bacterial groups, though the clinical significance of these shifts is still being worked out.
For patients and their families, the practical reality is a lifetime of medication management, blood draws to monitor drug levels, and the constant tension between giving enough immunosuppression to prevent rejection and not so much that infections or metabolic complications take over. It requires a level of medical engagement that goes far beyond what most people associate with recovering from surgery.